IASLC 7th Latin American Conference on Lung Cancer (LALCA 2016)

Individualizing the treatment of advanced NSCLC
Individualizar el tratamiento de CPCNP avanzado

Chaired by Carlos Gil Ferreira

14:00–15:00, Saturday 27th August  2016, Panama Salon 1, Level 4, El Riu Plaza Hotel
Simultaneous translation from English to Spanish | Traducción simultánea de inglés a español

Scientific summary

A documented account of the symposium presentations, associated discussions and video highlights. Available in English or español.
Click on your chosen version to download.

LALCA2016_SS THUMBLALCA2016 Scientific Summary Spanish

  • Chair: Carlos Gil Ferreira (Brazil)
    Welcome and introduction
    Bienvenida y presentación

    Carlos Gil

    Mauricio Cuello (Uruguay)
    Management of non-squamous NSCLC patients without EGFR/ALK mutations
    Manejo de pacientes con CPCNP no escamoso sin mutación EGFR/ALK
    Mauricio Cuello Headshot

    Johan Vansteenkiste (Belgium)
    Navigating the advanced squamous NSCLC patient pathway
    Recorriendo el camino del CPCNP escamoso avanzado
    Vansteenkiste Pic

    Carlos Gil Ferreira (Brazil)
    Closing remarks
    Notas de Clausura

  • After attending this symposium, learners should be able to:

    –– Assess the new treatment and diagnosis paradigms for non-mutated advanced and metastatic non-squamous NSCLC, and explain how to best apply them to individualized patient care in a Latin-American context

    –– Describe the rapidly expanding and complex range of treatment and diagnosis options for advanced and metastatic squamous NSCLC, and explain how to best apply them to individualized patient care in a Latin-American context

    Después de asistir a este simposio, los participantes serán capaces de:

    –– Evaluar los nuevos paradigmas del tratamiento y del diagnóstico para CPCNP avanzado sin mutación y metastásico no escamoso y explicar cómo aplicarlos mejor en el cuidado individualizado del paciente en el contexto de América latina

    –– Describir la rápida y compleja tasa de expansión de opciones de diagnóstico y tratamiento para CPCNP metastásico escamoso y explicar cómo aplicarlas mejor en el cuidado individualizado del paciente en el contexto de América latina

  • Dear Colleagues,

    Thank you for attending the satellite symposium entitled ‘Individualizing the treatment of advanced NSCLC ’ at the IASLC 7th Latin American Conference on Lung Cancer (LALCA 2016).

    Panama City provided a cosmopolitan and culturally vibrant host city for this conference that brought together a unique community of medical professionals from across the Latin–American region.

    The aim of the symposium was to facilitate the management of squamous and nonsquamous NSCLC, and the implementation of new discoveries in clinical practice. It also addressed the challenges facing clinicians in the Latin–American region in an increasingly complex treatment landscape.

    During this session, the expert Faculty guided us through this complexity by placing the latest developments in advanced NSCLC into the context of treatment. They provided their insights into how we can use our biological knowledge not only to improve treatment pathways, but also to maximize treatment outcomes by understanding different approaches.

    We hope that you found this symposium educational and that it has furthered your understanding of this evolving field. Yours faithfully

    Yours faithfully,

    Carlos Gil Ferreira – Chair

    Estimados colegas,

    Estimados colegas, Gracias por haber asistido al simposio satélite titulado “Individualizar el tratamiento de CPCNP avanzado” en la 7a Conferencia Latinoamericana sobre Cáncer de Pulmón (LALCA 2016) de la Asociación Internacional para el Estudio del Cáncer de Pulmón (IASLC).

    La ciudad de Panamá brindó un marco cosmopolita y cargado de cultura para albergar a esta conferencia que reunió a una comunidad especial de profesionales de la medicina de todas las regiones de América Latina.

    El objetivo de este simposio fue posibilitar el manejo del CPCNP escamoso y no escamoso y la implementación de los nuevos descubrimiento en la práctica clínica. También abordó los desafíos a los que se enfrentan los médicos en la región de América Latina en un panorama de tratamiento cada vez más complejo.

    Durante la sesión, el personal académico especializado nos guió a través de esta complejidad ubicando los últimos desarrollos sobre CPCNP avanzado en el contexto del tratamiento. Presentaron sus ideas sobre cómo podemos utilizar nuestro conocimiento biológico no solo para mejorar el tratamiento, sino también para maximizar los resultados del tratamiento a través de la comprensión de los diferentes enfoques.

    Esperamos que haya encontrado este simposio educativo y que contribuya a mejorar su comprensión sobre este campo en evolución.

    Atentamente,

    Carlos Gil Ferreira – Presidente

  • Carlos Gil Ferreira (Symposium Chair)
    Brazilian National Cancer Institute, Rio de Janeiro, Brazil

    Dr Ferreira graduated in Medicine from the Federal University of Juiz de Fora (1992) and completed his PhD in Experimental Oncology at the Free University of Amsterdam (2001).

    From 2002 to 2015 he was a senior researcher and head of the Clinical Research Service of the National Cancer Institute (INCA), where he held the following positions: Head of the Clinical Research Division, Head of the Scientific Program of Clinical Research, Creator and Principal Investigator of the National Tumor Bank and DNA (BNT), Coordinator of the National Network of Drug Development Anticancer (REDEFAC/SCTIE/MS) and Coordinator of the National Network of Clinical Research on Cancer (RNPCC/SCTIE/MS). Since 2015 Dr Ferreira has been the Research Coordinator in Oncology D’Or Institute for Research and Education.
    Outside of his institutional work, Dr Ferreira holds the following positions: Member of the Scientific Committee (CCVISA) of the National Health Surveillance Agency (ANVISA); Chair of the Latin American Oncology Consortium (LAOC), Co-Chair of the Career Development Fellowship Committee and the International Association for the Study of Lung Cancer (IASLC); Member of the International Affairs Committee of the American Association for Cancer Research (AACR); Director in Brazil of the International Network for Cancer Treatment and Research (INCTR); and Member of the Advisory Committee Americas Health Foundation (AHF). Dr Ferreira has a particular interest in health innovation projects, having worked with the government and commercial sectors in projects related to the development of diagnostic kits, new drugs and health economics.

    Johan Vansteenkiste
    University Hospital Leuven, Belgium

    Johan Vansteenkiste is Professor of Internal Medicine in the Faculty of Medicine at the Catholic University of Leuven, Belgium, and Head of Clinic in the Respiratory Oncology Unit and its Clinical Trial Unit at the Leuven University Hospital. Professor Vansteenkiste studied Medicine at the University of Leuven before becoming a Board Certified Pulmonologist-Oncologist. He had additional training in Respiratory Oncology at the European School of Oncology in Milan, Italy, and in Respiratory Endoscopy at the Laser Centre in Marseille, France, before gaining his PhD at the University of Leuven in 1996.

    Professor Vansteenkiste is an active member of different international societies such as ESMO, IASLC, ASCO, ERS and others. He was Secretary of the Thoracic Oncology Assembly of the ERS and member of the ERS School Board in 2009-2012. He was member of the Board of Directors of IASLC in 2009-2013. He is member of the ESMO Lung Educational Group and Guidelines Group, and chaired the European Lung Cancer Conference in April 2015. He is the principal investigator or co-investigator in several clinical trials in the area of lung cancer. He is Associate Editor of the Annals of Oncology, member of the editorial board of several other journals, and author or co-author of more than 250 peer-reviewed papers and book chapters.

    Mauricio Cuello
    Hospital de Clínicas Montevideo, Uruguay

    Dr Mauricio Cuello became a Doctor in Medicine at the Universidad de la Republica, UdelaR, Montevideo-Uruguay in 2000. In 2004, he specialized in Medical Oncology at Hospital de Clinicas UdelaR. He embarked on a Fellowship in Thoracic Oncology at the Hospital Germans trias i Pujol, Badalona, Barcelona, Spain from 2004–2009.

    Now Dr Cuello is an Associate Professor at the Department of Oncology, Hospital de Clínicas, Montevideo, Uruguay and has been there since 2011.

    His research activities include being the Coordinator of the Uruguayan Cooperative Oncology Group GOCUR and Director of the Oncology Respiratory Disease Unit at the Department of Oncology, Hospital de Clinicas, UdelaR from 2011 onwards. He has also been the Deputy Director at the National Cancer Institute since 2015. In his professional career, Dr Cuello has been the Clinical Coordinator in the Department of Oncology, Institute Dexeus, Barcelona, Spain from 2007–2011 and the Trial Clinical Manager at Boehringer Ingelheim, Barcelona, Spain from 2009–2011.